This test is most useful if any of these apply to you.
H. pylori has relatives that can cause stomach inflammation. Some are associated with pigs, cats, or dogs, although the source of an individual infection is often uncertain. Most human evidence about gastric non-pylori Helicobacter comes from stomach biopsies or stomach fluid. Finding bacterial DNA in stool is a different measurement.
This stool qPCR measurement is exploratory. The cited studies do not establish its accuracy for diagnosing stomach infection, its usefulness for screening healthy people, or its ability to confirm successful treatment. There is no validated stool CFU/g threshold that separates harmless detection from disease.
qPCR copies selected stretches of bacterial DNA and estimates how much is present. This test reports a grouped non-pylori Helicobacter result in CFU/g stool. CFU stands for colony-forming units, a term normally used when bacteria are grown in a laboratory. With qPCR, the reported quantity is derived from DNA and laboratory calibration; it is not a direct count of living bacterial colonies.
The catalog does not specify the genes targeted, the individual species covered, or how the DNA measurement is calibrated to CFU/g stool. A grouped positive result therefore cannot establish that you carry H. suis or any other particular species.
Helicobacter species are often divided into gastric and enterohepatic groups. Gastric species include H. suis, H. bizzozeronii, H. felis, and H. heilmannii, which can colonize the stomach. Enterohepatic species are associated with the intestines or liver and bile ducts; examples include H. cinaedi, H. bilis, and H. canis. These are biological groupings, and coverage of each species depends on the assay. Older studies often used the name H. heilmannii as a catch-all for several gastric species, including H. suis. Today that name refers to one specific cat-associated species, so older findings do not always map onto current species names.
In a Japanese study, about one in five selected people with gastric disease, negative routine H. pylori testing, and no previous H. pylori eradication had non-pylori Helicobacter detected in stomach biopsies. Belgian research found these organisms in roughly 28% to 29% of selected people with otherwise unexplained gastritis, ulcers, or gastric MALT lymphoma. These findings describe particular clinical groups tested in stomach tissue; they do not estimate your chance of infection from symptoms or predict this stool test's performance.
Japanese biopsy studies have linked H. suis infection to a crack-like or nodular appearance of the stomach lining. An Israeli biopsy study found H. bizzozeronii most often and frequently detected it alongside H. pylori. Symptoms and endoscopic findings were broadly similar across infection groups, so symptoms alone did not identify which bacteria were present.
Gastric non-pylori Helicobacter has also been associated with gastric MALT lymphoma. This is a cancer of immune cells in the stomach lining. That association does not make a positive stool DNA result a cancer diagnosis, and this assay has no established role in estimating your cancer risk.
H. cinaedi can cause bloodstream infection, particularly in people with weakened immune defenses. Human studies have recovered matching strains from blood and stool, supporting the intestine as one possible source. Those findings involved cultures and species identification. A grouped stool qPCR result cannot diagnose bloodstream infection or establish that H. cinaedi is present.
The Parkinson's findings come from stomach biopsies. In a study of 60 people with Parkinson's disease, H. suis detection was associated with a higher rate of death during follow-up after adjustment for age at Parkinson's diagnosis and sex. The estimated rate was about 12 times higher, but there were only eight deaths. The uncertainty was very wide, extending from about one to 103 times higher.
H. suis detection was also associated with lower blood pressure while standing. This was not evidence of a larger blood pressure drop on standing. These observations do not establish that the organism causes Parkinson's, that treating it improves survival, or that this stool assay can predict neurological disease.
The accuracy of this particular stool assay cannot be inferred from studies of H. pylori PCR, older broad Helicobacter PCR methods, or saliva testing. A negative result cannot reliably exclude gastric infection, and the probability that a positive represents clinically important infection also remains uncertain.
An older study in children detected non-pylori species in stool but could not establish whether they caused illness. Several remained PCR-positive after their H. pylori stool antigen tests became negative. That study does not show that a non-pylori stool finding usually represents brief passage or spontaneous clearance.
Repeated detection shows that bacterial DNA was found on more than one occasion. It does not establish the species, the site of infection, or whether the bacteria caused symptoms. Changes in the number may reflect biological changes, sampling differences, or laboratory variation. A meaningful change in this stool measurement has not been defined, and a falling or negative result has not been validated as proof of cure.
Evidence-backed interventions that affect your Non-Pylori Helicobacter spp. level
Non-Pylori Helicobacter spp. is best interpreted alongside these tests.
An at-home stool and urine test integrating microbiome balance, pathogens, digestion, permeability, immune activity, gut metabolites, and neurotransmitter patterns to clarify what is driving bloating, food reactions, fatigue, brain fog, and mood shifts.